Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Gross Profit (2023 - 2025)

Krystal Biotech's Gross Profit history spans 3 years, with the latest figure at $100.5 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 16.63% year-over-year to $100.5 million; the TTM value through Dec 2025 reached $366.1 million, up 35.35%, while the annual FY2025 figure was $366.1 million, 35.35% up from the prior year.
  • Gross Profit for Q4 2025 was $100.5 million at Krystal Biotech, up from $93.5 million in the prior quarter.
  • Across five years, Gross Profit topped out at $100.5 million in Q4 2025 and bottomed at $8.3 million in Q3 2023.
  • The 3-year median for Gross Profit is $80.2 million (2024), against an average of $68.4 million.
  • The largest annual shift saw Gross Profit surged 825.92% in 2024 before it increased 16.63% in 2025.
  • A 3-year view of Gross Profit shows it stood at $39.3 million in 2023, then soared by 119.43% to $86.2 million in 2024, then rose by 16.63% to $100.5 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Gross Profit are $100.5 million (Q4 2025), $93.5 million (Q3 2025), and $88.8 million (Q2 2025).